查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1424966

皮膚替代品和替代品的全球市場：市場規模和份額分析（按產品、類別、應用和最終用戶）、工業需求預測（截至 2030 年）

Skin Replacements and Substitutes Market Size and Share Analysis by Product, Class, Application, End User - Global Industry Demand Forecast to 2030
出版日期: | 出版商: Prescient & Strategic Intelligence | 英文 350 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

到 2030 年，全球皮膚替代品市場規模預計將達到 18.692 億美元，2024 年至 2030 年複合年增長率為 7.0%。 這是由於越來越多的公民在外表上花更多的錢，燒傷的發生率不斷增加，交通事故的發生率不斷增加，預期壽命猛增，皮膚病和慢性病的患病率不斷增加。 據世界衛生組織稱，印度每年有近100萬人遭受重度和中度燒傷。 印度的高殘疾調整生命年是由多種原因造成的，其中包括燒傷。

對外在美的興趣日益濃厚：

因慢性病或其他原因皮膚受損的人們越來越多地尋求治療來改善外表。 此外，醫學領域的技術創新已經提供了多種可用作皮膚替代品的產品，例如去細胞皮膚替代品。 在這些產品中，尼龍網充當真皮，矽膠膜充當表皮。 然後將其植入豬膠原蛋白中，並透過化學黏合黏附在傷口底部。

深度燒傷會破壞皮膚的兩層（真皮和表皮）並使它們暴露於微生物，這可能導致感染和進一步的併發症。 因此，建議及時進行醫療指導和手術。 滅菌後，人造皮膚具有促進細胞激素和生長因子釋放以再生受損組織的能力。 移植物的寬度、開口和連通孔應該適合新皮膚再生。

傷口護理診所和醫院持續佔據市場主導地位：

傷口護理診所和醫院是最大的最終用戶，因為它們擁有複雜燒傷病例所需的先進設備、專家、必要的藥物和技術。 隨著越來越多人患有皮膚病，到這些醫療中心的就診的人數也在增加。 此外，由於手術後會造成嚴重傷口，因此此類皮膚更換手術通常是整個術後護理計畫的一部分。

亞太地區的成長機會：

由於醫療領域的進步和對皮膚護理的高需求，北美在市場上佔據主導地位。 此外，各大公司正在與醫院、美容中心和傷口護理診所合作，行銷和開發皮膚替代品和替代品，目標是獲得 FDA 批准。 例如，2021 年 6 月，Mallinckrodt Pharmaceuticals 的一款名為 StrataGraft 的新型皮膚產品獲得 FDA 批准。 如果一些深層皮膚層和真皮成分在熱燒傷後保持完整，則該產品可以減少自體移植的需要。

由於整容手術需求不斷增長以及糖尿病足潰瘍 (DFU) 等皮膚病的高發，亞太地區 (APAC) 成為成長最快的市場。 15-25% 的糖尿病患者會在某個時候出現 DFU。 據世界衛生組織稱，中國糖尿病患者人數預計將從2016年的1.1億增加到2040年的1.5億人。 此外，2019 年至 2021 年間，印度新診斷出 3,100 萬人患有糖尿病。

本報告分析了全球皮膚替代品和替代品市場，包括市場的基本結構和最新情況、主要推動和限制因素，以及全球、按地區和主要國家的市場規模趨勢預測。（金額基礎，2017 -2030），按產品、類別、應用程式和最終用戶劃分的詳細趨勢、當前市場競爭狀況以及主要公司的概況進行了調查。

目錄

第1章研究範圍

第2章研究方法

第 3 章執行摘要

第 4 章市場指標

第5章產業展望

  • 市場動態
    • 趨勢
    • 促進因素
    • 抑制因素/挑戰
    • 促進/抑制因子影響分析
  • 新型冠狀病毒感染 (COVID-19) 的影響
  • 波特五力分析

第6章世界市場

  • 摘要
  • 市場收入：依產品分類（2017-2030 年）
  • 市場收入：依類別劃分（2017-2030 年）
    • I 類市場收入：按類型劃分（2017-2030 年）
    • 第二類市場收入：依類型劃分（2017-2030 年）
    • 第三類市場收入：依類型分類（2017-2030 年）
  • 市場收入：依應用分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）
  • 市場收入：按地區劃分（2017-2030 年）

第7章北美市場

  • 摘要
  • 市場收入：依產品分類（2017-2030 年）
  • 市場收入：依類別劃分（2017-2030 年）
    • I 類市場收入：按類型劃分（2017-2030 年）
    • 第二類市場收入：依類型劃分（2017-2030 年）
    • 第三類市場收入：依類型劃分（2017-2030 年）
  • 市場收入：依應用分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）
  • 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第 11 章中東與非洲 (MEA) 市場

第12章美國市場

  • 摘要
  • 市場收入：依產品分類（2017-2030 年）
  • 市場收入：依類別劃分（2017-2030 年）
    • I 類市場收入：按類型劃分（2017-2030 年）
    • 第二類市場收入：依類型劃分（2017-2030 年）
    • 第三類市場收入：依類型劃分（2017-2030 年）
  • 市場收入：依應用分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）

第13章加拿大市場

第14章德國市場

第15章法國市場

第16章英國市場

第17章義大利市場

第18章西班牙市場

第19章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

  • 市場參與者及其提供的產品/服務列表
  • 主要公司的競爭基準
  • 各大公司的產品基準
  • 近期策略發展狀況

第30章公司簡介

  • Acelity L.P. Inc.
  • MiMedx Group Inc.
  • Organogenesis Inc.
  • Vericel Corporation
  • FUJIFILM Cellular Dynamics Inc.
  • Smith & Nephew plc
  • Integra LifeSciences Holdings Corporation
  • AlloSource
  • MatTek Corporation

第31章 附錄

簡介目錄
Product Code: 11704

The global skin replacements and substitutes market size is set to be USD 1,869.2 million by 2030, witnessing 7.0% CAGR between 2024 and 2030. This will be due to the increasing number of citizens spending on appearance enhancement, rising incidence of burns, growing rate of road accidents, surging life expectancy, and escalating prevalence of skin and chronic disease. As per the WHO, nearly 1 million people in India get severe and moderate burns each year. The high disability-adjusted life-years in India are due to burns and many other causes.

Increasing Focus on Enhance Appearance of Skin

People with skin damage due to chronic diseases and other reasons are increasingly seeking remedies to enhance their appearance. Further, due to the innovations in the healthcare sector, various products are available for use as skin replacement, such as acellular substitutes; these products are cost-effective and efficient. In these products, a nylon mesh works as the dermis, and a silicon membrane works as the epidermis. It is then implanted into porcine collagen and connected by chemical bonds for attachment to the wound base.

Deep burns can destroy both layers of the skin (dermis and epidermis), exposing them to microorganisms, which can cause infections and further complications. Therefore, quick medical guidance or surgery is advised. Artificial skin, after sterilization, has the capacity to enhance the release of cytokines and growth factors for regenerating the destroyed tissue. The width, orifice, and interconnecting pores of the graft should be ideal for the regeneration of new skin.

Continued Dominance of Wound Care Clinics and Hospitals on Market

Wound care clinics and hospitals are the largest end users as they have sophisticated facilities, expert professionals, necessary medication, and the technology required for complicated burn cases. With an increasing number of people suffering from dermatological diseases, the footfall at these healthcare centers is rising. Moreover, severe wounds are caused after surgery; hence, such skin replacement procedures are often part of the overall post-operative care regimen.

Growing Opportunities in APAC

North America is dominating the market due to the advancements in the healthcare sector and a high demand for skincare. Moreover, the key market players are collaborating with hospitals, cosmetic centers, and wound care clinics to sell and advance their skin replacement and substitute products and pursuing the approval of the FDA for them. For instance, in June 2021 Mallinckrodt Pharmaceuticals received the FDA approval for a novel skin product, called StrataGraft. It can reduce the requirement for autografts if some part of the deeper skin layers and dermal elements remains intact after a thermal burn injury.

APAC is the fastest-growing market due to the increasing demand for cosmetic procedures and the high prevalence of diabetic foot ulcers and other skin issues. Between 15 and 25% of the population with diabetes mellitus would develop a DFU at some point. As per the WHO, diabetic population in China is expected to reach 150 million by 2040 from 110 million in 2016. Moreover, India registered 31 million new diabetes diagnoses in 2019-2021.

Some of the key players in the skin and replacements and substitutes market are Acelity L.P. Inc., MiMedx Group Inc., Organogenesis Inc., Vericel Corporation, FUJIFILM Cellular Dynamics Inc., Smith & Nephew plc, Integra LifeSciences Holdings Corporation, AlloSource, and MatTek Corporation.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by product
    • 1.4.2. Market size breakdown, by class
    • 1.4.3. Market size breakdown, by application
    • 1.4.4. Market size breakdown, by end user
    • 1.4.5. Market size breakdown, by region
    • 1.4.6. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Product (2017-2030)
  • 6.3. Market Revenue, by Class (2017-2030)
    • 6.3.1. Class I market revenue, by type (2017-2030)
    • 6.3.2. Class II market revenue, by type (2017-2030)
    • 6.3.3. Class III market revenue, by type (2017-2030)
  • 6.4. Market Revenue, by Application (2017-2030)
  • 6.5. Market Revenue, by End User (2017-2030)
  • 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Product (2017-2030)
  • 7.3. Market Revenue, by Class (2017-2030)
    • 7.3.1. Class I market revenue, by type (2017-2030)
    • 7.3.2. Class II market revenue, by type (2017-2030)
    • 7.3.3. Class III market revenue, by type (2017-2030)
  • 7.4. Market Revenue, by Application (2017-2030)
  • 7.5. Market Revenue, by End User (2017-2030)
  • 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Product (2017-2030)
  • 8.3. Market Revenue, by Class (2017-2030)
    • 8.3.1. Class I market revenue, by type (2017-2030)
    • 8.3.2. Class II market revenue, by type (2017-2030)
    • 8.3.3. Class III market revenue, by type (2017-2030)
  • 8.4. Market Revenue, by Application (2017-2030)
  • 8.5. Market Revenue, by End User (2017-2030)
  • 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Product (2017-2030)
  • 9.3. Market Revenue, by Class (2017-2030)
    • 9.3.1. Class I market revenue, by type (2017-2030)
    • 9.3.2. Class II market revenue, by type (2017-2030)
    • 9.3.3. Class III market revenue, by type (2017-2030)
  • 9.4. Market Revenue, by Application (2017-2030)
  • 9.5. Market Revenue, by End User (2017-2030)
  • 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Product (2017-2030)
  • 10.3. Market Revenue, by Class (2017-2030)
    • 10.3.1. Class I market revenue, by type (2017-2030)
    • 10.3.2. Class II market revenue, by type (2017-2030)
    • 10.3.3. Class III market revenue, by type (2017-2030)
  • 10.4. Market Revenue, by Application (2017-2030)
  • 10.5. Market Revenue, by End User (2017-2030)
  • 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Product (2017-2030)
  • 11.3. Market Revenue, by Class (2017-2030)
    • 11.3.1. Class I market revenue, by type (2017-2030)
    • 11.3.2. Class II market revenue, by type (2017-2030)
    • 11.3.3. Class III market revenue, by type (2017-2030)
  • 11.4. Market Revenue, by Application (2017-2030)
  • 11.5. Market Revenue, by End User (2017-2030)
  • 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Product (2017-2030)
  • 12.3. Market Revenue, by Class (2017-2030)
    • 12.3.1. Class I market revenue, by type (2017-2030)
    • 12.3.2. Class II market revenue, by type (2017-2030)
    • 12.3.3. Class III market revenue, by type (2017-2030)
  • 12.4. Market Revenue, by Application (2017-2030)
  • 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Product (2017-2030)
  • 13.3. Market Revenue, by Class (2017-2030)
    • 13.3.1. Class I market revenue, by type (2017-2030)
    • 13.3.2. Class II market revenue, by type (2017-2030)
    • 13.3.3. Class III market revenue, by type (2017-2030)
  • 13.4. Market Revenue, by Application (2017-2030)
  • 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Product (2017-2030)
  • 14.3. Market Revenue, by Class (2017-2030)
    • 14.3.1. Class I market revenue, by type (2017-2030)
    • 14.3.2. Class II market revenue, by type (2017-2030)
    • 14.3.3. Class III market revenue, by type (2017-2030)
  • 14.4. Market Revenue, by Application (2017-2030)
  • 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Product (2017-2030)
  • 15.3. Market Revenue, by Class (2017-2030)
    • 15.3.1. Class I market revenue, by type (2017-2030)
    • 15.3.2. Class II market revenue, by type (2017-2030)
    • 15.3.3. Class III market revenue, by type (2017-2030)
  • 15.4. Market Revenue, by Application (2017-2030)
  • 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Product (2017-2030)
  • 16.3. Market Revenue, by Class (2017-2030)
    • 16.3.1. Class I market revenue, by type (2017-2030)
    • 16.3.2. Class II market revenue, by type (2017-2030)
    • 16.3.3. Class III market revenue, by type (2017-2030)
  • 16.4. Market Revenue, by Application (2017-2030)
  • 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Product (2017-2030)
  • 17.3. Market Revenue, by Class (2017-2030)
    • 17.3.1. Class I market revenue, by type (2017-2030)
    • 17.3.2. Class II market revenue, by type (2017-2030)
    • 17.3.3. Class III market revenue, by type (2017-2030)
  • 17.4. Market Revenue, by Application (2017-2030)
  • 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Product (2017-2030)
  • 18.3. Market Revenue, by Class (2017-2030)
    • 18.3.1. Class I market revenue, by type (2017-2030)
    • 18.3.2. Class II market revenue, by type (2017-2030)
    • 18.3.3. Class III market revenue, by type (2017-2030)
  • 18.4. Market Revenue, by Application (2017-2030)
  • 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Product (2017-2030)
  • 19.3. Market Revenue, by Class (2017-2030)
    • 19.3.1. Class I market revenue, by type (2017-2030)
    • 19.3.2. Class II market revenue, by type (2017-2030)
    • 19.3.3. Class III market revenue, by type (2017-2030)
  • 19.4. Market Revenue, by Application (2017-2030)
  • 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Product (2017-2030)
  • 20.3. Market Revenue, by Class (2017-2030)
    • 20.3.1. Class I market revenue, by type (2017-2030)
    • 20.3.2. Class II market revenue, by type (2017-2030)
    • 20.3.3. Class III market revenue, by type (2017-2030)
  • 20.4. Market Revenue, by Application (2017-2030)
  • 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Product (2017-2030)
  • 21.3. Market Revenue, by Class (2017-2030)
    • 21.3.1. Class I market revenue, by type (2017-2030)
    • 21.3.2. Class II market revenue, by type (2017-2030)
    • 21.3.3. Class III market revenue, by type (2017-2030)
  • 21.4. Market Revenue, by Application (2017-2030)
  • 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Product (2017-2030)
  • 22.3. Market Revenue, by Class (2017-2030)
    • 22.3.1. Class I market revenue, by type (2017-2030)
    • 22.3.2. Class II market revenue, by type (2017-2030)
    • 22.3.3. Class III market revenue, by type (2017-2030)
  • 22.4. Market Revenue, by Application (2017-2030)
  • 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Product (2017-2030)
  • 23.3. Market Revenue, by Class (2017-2030)
    • 23.3.1. Class I market revenue, by type (2017-2030)
    • 23.3.2. Class II market revenue, by type (2017-2030)
    • 23.3.3. Class III market revenue, by type (2017-2030)
  • 23.4. Market Revenue, by Application (2017-2030)
  • 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Product (2017-2030)
  • 24.3. Market Revenue, by Class (2017-2030)
    • 24.3.1. Class I market revenue, by type (2017-2030)
    • 24.3.2. Class II market revenue, by type (2017-2030)
    • 24.3.3. Class III market revenue, by type (2017-2030)
  • 24.4. Market Revenue, by Application (2017-2030)
  • 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Product (2017-2030)
  • 25.3. Market Revenue, by Class (2017-2030)
    • 25.3.1. Class I market revenue, by type (2017-2030)
    • 25.3.2. Class II market revenue, by type (2017-2030)
    • 25.3.3. Class III market revenue, by type (2017-2030)
  • 25.4. Market Revenue, by Application (2017-2030)
  • 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Product (2017-2030)
  • 26.3. Market Revenue, by Class (2017-2030)
    • 26.3.1. Class I market revenue, by type (2017-2030)
    • 26.3.2. Class II market revenue, by type (2017-2030)
    • 26.3.3. Class III market revenue, by type (2017-2030)
  • 26.4. Market Revenue, by Application (2017-2030)
  • 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Product (2017-2030)
  • 27.3. Market Revenue, by Class (2017-2030)
    • 27.3.1. Class I market revenue, by type (2017-2030)
    • 27.3.2. Class II market revenue, by type (2017-2030)
    • 27.3.3. Class III market revenue, by type (2017-2030)
  • 27.4. Market Revenue, by Application (2017-2030)
  • 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Product (2017-2030)
  • 28.3. Market Revenue, by Class (2017-2030)
    • 28.3.1. Class I market revenue, by type (2017-2030)
    • 28.3.2. Class II market revenue, by type (2017-2030)
    • 28.3.3. Class III market revenue, by type (2017-2030)
  • 28.4. Market Revenue, by Application (2017-2030)
  • 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. Acelity L.P. Inc.
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. MiMedx Group Inc.
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Organogenesis Inc.
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. Vericel Corporation
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. FUJIFILM Cellular Dynamics Inc.
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. Smith & Nephew plc
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. Integra LifeSciences Holdings Corporation
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. AlloSource
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. MatTek Corporation
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports